Dana Brantley-Sieders
Faculty Member

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

  1. VAMP-associated protein B (VAPB) promotes breast tumor growth by modulation of Akt activity. Rao M, Song W, Jiang A, Shyr Y, Lev S, Greenstein D, Brantley-Sieders D, Chen J (2012) PLoS One 7(10): e46281
    › Primary publication · 23049696 (PubMed) · PMC3462209 (PubMed Central)
  2. Local breast cancer spatial patterning: a tool for community health resource allocation to address local disparities in breast cancer mortality. Brantley-Sieders DM, Fan KH, Deming-Halverson SL, Shyr Y, Cook RS (2012) PLoS One 7(9): e45238
    › Primary publication · 23028869 (PubMed) · PMC3460936 (PubMed Central)
  3. Effects of cancer-associated EPHA3 mutations on lung cancer. Zhuang G, Song W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, Guo Y, Shyr Y, Lin L, Carbone DP, Brantley-Sieders DM, Chen J (2012) J Natl Cancer Inst 104(15): 1182-97
    › Primary publication · 22829656 (PubMed) · PMC3611812 (PubMed Central)
  4. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, Chen J (2011) PLoS One 6(9): e24426
    › Primary publication · 21935409 (PubMed) · PMC3174170 (PubMed Central)
  5. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C, Chen J (2010) Cancer Res 70(1): 299-308
    › Primary publication · 20028874 (PubMed) · PMC3859619 (PubMed Central)
  6. Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Vaught D, Chen J, Brantley-Sieders DM (2009) Mol Biol Cell 20(10): 2572-81
    › Primary publication · 19321667 (PubMed) · PMC2682598 (PubMed Central)
  7. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Li B, Vincent A, Cates J, Brantley-Sieders DM, Polk DB, Young PP (2009) Cancer Res 69(1): 338-48
    › Primary publication · 19118019 (PubMed) · PMC2651676 (PubMed Central)
  8. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J (2005) FASEB J 19(13): 1884-6
    › Primary publication · 16166198 (PubMed)
  9. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J (2005) Oncogene 24(53): 7859-68
    › Primary publication · 16103880 (PubMed)
  10. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Brantley-Sieders D, Schmidt S, Parker M, Chen J (2004) Curr Pharm Des 10(27): 3431-42
    › Primary publication · 15544526 (PubMed)